175 related articles for article (PubMed ID: 38090571)
1. Corrigendum: Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6
Li T; Lin X; Shen B; Zhang W; Liu Y; Liu H; Wang Y; Zheng L; Zhi F
Front Immunol; 2023; 14():1297103. PubMed ID: 38090571
[TBL] [Abstract][Full Text] [Related]
2. Corrigendum: Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6
Li T; Lin X; Shen B; Zhang W; Liu Y; Liu H; Wang Y; Zheng L; Zhi F
Front Immunol; 2023; 14():1139000. PubMed ID: 36911688
[TBL] [Abstract][Full Text] [Related]
3.
Li T; Lin X; Shen B; Zhang W; Liu Y; Liu H; Wang Y; Zheng L; Zhi F
Front Immunol; 2022; 13():1047570. PubMed ID: 36531991
[TBL] [Abstract][Full Text] [Related]
4. Role of Akkermansia muciniphila in the development of nonalcoholic fatty liver disease: current knowledge and perspectives.
Han Y; Li L; Wang B
Front Med; 2022 Oct; 16(5):667-685. PubMed ID: 36318353
[TBL] [Abstract][Full Text] [Related]
5. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
6.
Han Y; Ling Q; Wu L; Wang X; Wang Z; Chen J; Zheng Z; Zhou Z; Jia L; Li L; Wang B
Gut Microbes; 2023; 15(1):2221485. PubMed ID: 37345844
[TBL] [Abstract][Full Text] [Related]
7. Alcoholic, Nonalcoholic, and Toxicant-Associated Steatohepatitis: Mechanistic Similarities and Differences.
Joshi-Barve S; Kirpich I; Cave MC; Marsano LS; McClain CJ
Cell Mol Gastroenterol Hepatol; 2015 Jul; 1(4):356-367. PubMed ID: 28210688
[TBL] [Abstract][Full Text] [Related]
8. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
Kim SK; Kim KI; Kim SR
Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
[TBL] [Abstract][Full Text] [Related]
9. Heat-Inactivated
Morrison MC; Gart E; Duyvenvoorde WV; Snabel J; Nielsen MJ; Leeming DJ; Menke A; Kleemann R
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216439
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
Perumpail RB; Wong RJ; Ahmed A; Harrison SA
Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD122 antibody restores specific CD8
Lacotte S; Slits F; Moeckli B; Peloso A; Koenig S; Tihy M; El Hajji S; Gex Q; Rubbia-Brandt L; Toso C
Oncoimmunology; 2023; 12(1):2184991. PubMed ID: 36891258
[TBL] [Abstract][Full Text] [Related]
12. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
Massoud O; Charlton M
Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
[TBL] [Abstract][Full Text] [Related]
14. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
15. Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets.
Chen Y; Wang W; Morgan MP; Robson T; Annett S
Front Endocrinol (Lausanne); 2023; 14():1148934. PubMed ID: 37361533
[TBL] [Abstract][Full Text] [Related]
16. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
17. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
19. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
20. Increase of α-dicarbonyls in liver and receptor for advanced glycation end products on immune cells are linked to nonalcoholic fatty liver disease and liver cancer.
Petriv N; Neubert L; Vatashchuk M; Timrott K; Suo H; Hochnadel I; Huber R; Petzold C; Hrushchenko A; Yatsenko AS; Shcherbata HR; Wedemeyer H; Lichtinghagen R; Falfushynska H; Lushchak V; Manns MP; Bantel H; Semchyshyn H; Yevsa T
Oncoimmunology; 2021 Feb; 10(1):1874159. PubMed ID: 33628620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
